Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

By 2023 and 2033, the Peptide Synthesis Market is projected to reach US$ 520.0 million and US$ 1.1 billion, respectively. The market is anticipated to expand at a CAGR of 8% over the course of the projected period. The peptide synthesis market is anticipated to grow at a CAGR of 7% from 2022 to 2032, according to Future Market Insights' (FMI) Peptide Synthesis Market study.

The prevalence of several peptide applications in the management of various lifestyle problems, including as malignancies, diabetes, and obesity, has a significant impact on the market's growth. Peptide synthesis in pharmaceutical manufacturing is increasingly being regarded as active in drug development due to their large chemical space, high biological activity, and low toxicity. This is expected to flourish the peptide synthesis market and increase the adoption of the peptide synthesis process.

Among other medicinal fields, peptides represent a multibillion dollar industry in oncology, diabetes, and obesity. Major pharmaceutical, biotechnology, and peptide synthesis companies have all made investments in the development of therapeutic and peptide-based vaccines as a result of the COVID-19 pandemic. The rising demand for peptide-based medicines and vaccines has also brought peptide synthesis to the fore.

Request Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-14257  

The peptide-based approach marks a pivotal point as peptides have demonstrated unique selectivity and specificity toward specific targets. CoVac-1 is a peptide-based vaccine candidate that combines SARS-CoV-2 T-cell epitopes derived from various viral proteins with the Toll-like receptor 1/2 agonist XS15 emulsified in Montanide ISA51 VG, with the goal of inducing profound SARS-CoV-2 T-cell immunity to combat COVID-19.

Such advancements have resulted in an emerging trend in peptide synthesis market, thereby surged the demand for reagents and equipment used in the production of peptides. The lack of a unified set of regulations has made obtaining approvals for therapeutic peptides toilsome, limiting their application areas. This is regarded as a major impediment to the growth of the global peptide synthesis market. Considering all of the above-mentioned factors, the peptide synthesis market size is expected to be around US$ 720 Mn by 2026.

Key Takeaways

  • Peptide synthesis market future trends suggests that the market is anticipated to be dominated by the reagents segment.
  • The historical performance of the peptide synthesis market was modest with the valuation of US$ 514 in 2021.
  • The APAC peptide synthesis market is expected to continue to grow at the fastest rate, owing to increased investments by pharmaceutical as well as increased R&D activities in the region’s countries.
  • Based on end use, pharmaceutical and biotechnology companies are expected to hold a significant market share due to the increasing use of peptides for therapeutic drug development.
  • By technology, the segment of solid-phase peptide synthesis is expected to advance at faster pace due to ease of peptide purification.

 “High prevalence of chronic diseases, and increased investments in the development of structure-based drug designs can all be attributed to North America’s large peptide synthesis market share as the rising number of cancer cases is expected to drive peptide synthesis market growth and as per the World Health Organization article, 18.1 million new cancer cases are reported worldwide each year. Add to that the demand for immunity-boosting drugs in the times of COVID-19 and the market potential seems conducive.” says an FMI analyst.

Competitive Landscape:

The global peptide synthesis market is dominated by the following companies:

CEM Corporation, Merck KGaA, PuroSynth, Syngene, Lonza, GenScript Biotech Corporation, Novo Nordisk A/S, Bachem Holding AG, ThermoFisher Scientific Inc., Gyros Protein Technologies, Creative Diagnostics, Biotage AB and AAPPTec among others.

Some peptide synthesis companies are expanding their market position through various strategies such as acquisitions, mergers, and research collaborations, whereas others are maintaining their market share by introducing new products.

  • CEM Corporation unveiled Liberty PRO, the world’s first large-scale automated microwave peptide synthesiser. The system can synthesise 1 kg of crude peptide per batch in reaction vessels ranging in size from 1 to 15 litres, with unrivalled purity, speed, and waste reduction fueling market revenue share.
  • Pfizer, Inc. and Imcyse SA have announced a research collaboration to develop Imotope, a specifically modified peptide. This peptide was developed to treat rheumatoid arthritis and the same augurs well for the future of peptide development.

Peptide Synthesis Market by Category

By Product and Services:

  • Reagents
  • Equipment
  • Services

By Technology:

  • Solid-phase peptide Synthesis
  • Solution-phase Peptide Synthesis
  • Hybrid & Recombinant Technology

By End Use:

  • Pharmaceuticals & Biotechnology Companies
  • CDMOs & CROs
  • Academics & Research Institutes


Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe